AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary ...

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Chronic Bronchitis. According to GlobalData, Phase II drugs for Chronic Bronchitis have a 77% phase transition ...

has approved the clinical trial protocol amendment proposal of the drug major AstraZeneca Pharma India to study the long-term efficacy and safety of Tozorakimab in participants with chronic ...

AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner ...

Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement. The Company ...

Sept 16 (Reuters) - Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...